The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Kaken to Snatch Up Aadi Subsidiary for US$100 Million to Establish Global Footprint
Kaken Pharmaceutical said on December 20 that it will acquire all shares of US pharma firm Aadi Subsidiary for US$100 million and pick up businesses related to the cancer drug Fyarro (sirolimus protein-bound particles for injectable suspension). Kaken is currently…
To read the full story
Related Article
- Kaken Closes US$103 Million Acquisition of Aadi Subsidiary
March 28, 2025
- Kaken Set to Take Stab at US Market with Vascular Malformation Drug
February 20, 2025
BUSINESS
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
- Boehringer Passes on Option for Nxera’s Schizophrenia Program
December 22, 2025
- Otsuka Kicks Off Global PIII of Phenylketonuria Drug
December 22, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…